Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the utility of sacituzumab govitecan-hziy in metastatic triple-negative breast cancer.
Howard A. “Skip” Burris, III, MD, FASCO, FACP, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the utility of sacituzumab govitecan-hziy (Trodelvy) in metastatic triple-negative breast cancer (TNBC).
Since being granted accelerated approval on April 22, 2020, sacituzumab govitecan has been used safely and effectively in the clinical setting for this patient population, says Burris. However, premedication with antiemetics is often necessary.
Additionally, the agent has demonstrated several encouraging efficacy signals, such as improved liver function tests and cancer-related symptoms, Burris explains.
Notably, the camptothecin toxin in sacituzumab govitecan has always been an agent of interest due to its active payload in irinotecan. As such, the mechanism of linking the toxin to an antibody suggests that patients will benefit significantly from this therapy, Burris concludes.